Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 11/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16619315 | 0.99 | RORC (0.49) | RORCBRD4PDE4APDE4BPDE4C | |
| SCHEMBL28068082 | 0.91 | RORC (0.49) | RORCBRD4PDE4APDE4BPDE4C | |
| SCHEMBL19971362 | 0.89 | RORC (0.48) | RORCBRD4PDE4APDE4BPDE4C | |
| SCHEMBL16618918 | 0.87 | RORC (0.51) | RORCBRD4PDE4APDE4BPDE4C | |
| SCHEMBL17971568 | 0.85 | METAP2 (0.41) | RORCPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL16626638 | 0.84 | RORC (0.47) | RORCBRD4PDE4APDE4BPDE4C | |
| Hydrochloric Acid SCHEMBL16618831 | 0.84 | METAP2 (0.41) | RORCMETAP2SCN9AHTR6NR1D1 | |
| SCHEMBL17971573 | 0.83 | RORC (0.51) | RORCBRD4HTR6KDM2B | |
| Hydrochloric Acid SCHEMBL16619011 | 0.83 | RORC (0.50) | RORCBRD4HTR6KDM2B | |
| SCHEMBL16626779 | 0.81 | RORC (0.50) | RORCBRD4HTR6NR1D1KDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052484-B1 | SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | DAE WOONG PHARMA (KR) | 2018-03-21 | — | — | EP | claimed |
| EP-3052484-B1 | SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | DAE WOONG PHARMA (KR) | 2018-03-21 | — | — | EP | disclosed |
| US-9676714-B2 | Sulfonylindole derivatives and method for preparing the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2017-06-13 | — | — | US | disclosed |
| US-9676714-B2 | Sulfonylindole derivatives and method for preparing the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2017-06-13 | — | — | US | disclosed |
| US-20160221946-A1 | SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2016-08-04 | — | — | US | disclosed |
| US-20160221946-A1 | SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2016-08-04 | — | — | US | disclosed |
| WO-2015050412-A1 | SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221946-A1 | SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | GIPR, PGC, SI | RORC 1067/4885BRD4 2190/4885PDE4A 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.